Abstract
Oral second-generation antipsychotics were introduced in the 1990s and long-acting injectables (LAIs; also known as depot) became available a decade later. LAIs used to be prescribed mainly to patients who did not adhere to treatment, and from personal clinical experience, patients still report today that they perceived it as a penalty to receive LAIs. After scarce prescribing until around 2010, the rate of LAIs being prescribed increased over the past decade, not only for schizophrenia but also off-label for bipolar disorder.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
